Literature DB >> 23053966

Genetic variants of GRIA1 are associated with susceptibility to schizophrenia in Korean population.

Won Sub Kang1, Jin Kyung Park, Su Kang Kim, Hae Jeong Park, Sang Min Lee, Ji Young Song, Joo-Ho Chung, Jong Woo Kim.   

Abstract

The α-amino-3-hydroxy-5-methyl-4-propionic acid (AMPA) receptors are important for glutamate synaptic transmission in the central nervous system. Glutamate receptor, ionotropic, AMPA receptor 1 gene (GRIA1) belongs to the family of AMPA receptors. There is increasing evidence that AMPA receptors dysfunction may be related to an increased susceptibility to schizophrenia. The aim of this study was therefore to investigate whether genetic polymorphisms of GRIA1 are associated with schizophrenia and their clinical symptoms (hallucinations and delusions) in Korean population. Five single nucleotide polymorphisms (rs1428920, rs1552834, rs1422889, rs10035143, and rs2926835) of the GRIA1 were genotyped in 218 schizophrenia patients and 380 healthy controls, using a direct sequencing. All patients were evaluated by the Operational Criteria Checklist for Psychotic Illness. The genotype and allelic frequencies of rs1428920 and rs2926835 showed significant association between schizophrenia and controls (rs1428920, permutation p = 0.008, 0.008; rs2926835, permutation p = 0.038, 0.041, respectively). A significantly increased risk of schizophrenia was associated with the A allele of rs1428920 and rs2926835 of GRIA1. Furthermore, we found that rs1428920 was weakly associated with hallucinations of schizophrenia, but this significance disappeared after multiple testing (permutation p = 0.119). These results suggest that GRIA1 polymorphism may have influence upon the risk of developing schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053966     DOI: 10.1007/s11033-012-1960-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  27 in total

1.  The structure of haplotype blocks in the human genome.

Authors:  Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler
Journal:  Science       Date:  2002-05-23       Impact factor: 47.728

2.  Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia.

Authors:  Concetta Crisafulli; Alberto Chiesa; Diana De Ronchi; Changsu Han; Soo-Jung Lee; Moon Ho Park; Ashwin A Patkar; Chi-Un Pae; Alessandro Serretti
Journal:  Neurosci Lett       Date:  2011-11-06       Impact factor: 3.046

3.  Evidence of linkage to psychosis on chromosome 5q33-34 in pedigrees ascertained for bipolar disorder.

Authors:  Berit Kerner; Diana L Brugman; Nelson B Freimer
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-01-05       Impact factor: 3.568

Review 4.  Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework.

Authors:  A H Fanous; K S Kendler
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

Review 5.  Glutamate receptor dynamics in dendritic microdomains.

Authors:  Thomas M Newpher; Michael D Ehlers
Journal:  Neuron       Date:  2008-05-22       Impact factor: 17.173

6.  Twin study refining psychotic symptom dimensions as phenotypes for genetic research.

Authors:  Alastair G Cardno; Frühling V Rijsdijk; Robin M Murray; Peter McGuffin
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-10-05       Impact factor: 3.568

Review 7.  Glutamate signaling in the pathophysiology and therapy of schizophrenia.

Authors:  Chieh-Hsin Lin; Hsien-Yuan Lane; Guochuan E Tsai
Journal:  Pharmacol Biochem Behav       Date:  2011-04-01       Impact factor: 3.533

8.  Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders.

Authors:  Monica Beneyto; Lars V Kristiansen; Akinwunmi Oni-Orisan; Robert E McCullumsmith; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2007-02-14       Impact factor: 7.853

9.  Expression profiles of schizophrenia susceptibility genes during human prefrontal cortical development.

Authors:  Kwang H Choi; Megan E Zepp; Brandon W Higgs; Cynthia S Weickert; Maree J Webster
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

10.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia.

Authors:  Cathryn M Lewis; Douglas F Levinson; Lesley H Wise; Lynn E DeLisi; Richard E Straub; Iiris Hovatta; Nigel M Williams; Sibylle G Schwab; Ann E Pulver; Stephen V Faraone; Linda M Brzustowicz; Charles A Kaufmann; David L Garver; Hugh M D Gurling; Eva Lindholm; Hilary Coon; Hans W Moises; William Byerley; Sarah H Shaw; Andrea Mesen; Robin Sherrington; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler; Jesper Ekelund; Tiina Paunio; Jouko Lönnqvist; Leena Peltonen; Michael C O'Donovan; Michael J Owen; Dieter B Wildenauer; Wolfgang Maier; Gerald Nestadt; Jean-Louis Blouin; Stylianos E Antonarakis; Bryan J Mowry; Jeremy M Silverman; Raymond R Crowe; C Robert Cloninger; Ming T Tsuang; Dolores Malaspina; Jill M Harkavy-Friedman; Dragan M Svrakic; Anne S Bassett; Jennifer Holcomb; Gursharan Kalsi; Andrew McQuillin; Jon Brynjolfson; Thordur Sigmundsson; Hannes Petursson; Elena Jazin; Tomas Zoëga; Tomas Helgason
Journal:  Am J Hum Genet       Date:  2003-06-11       Impact factor: 11.025

View more
  7 in total

Review 1.  Neurodevelopmental Disorders Associated with PSD-95 and Its Interaction Partners.

Authors:  Amanda M Levy; Paulino Gomez-Puertas; Zeynep Tümer
Journal:  Int J Mol Sci       Date:  2022-04-15       Impact factor: 6.208

2.  Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia.

Authors:  Parisa Afshari; Marina Myles-Worsley; Ori S Cohen; Josepha Tiobech; Stephen V Faraone; William Byerley; Frank A Middleton
Journal:  Mol Neuropsychiatry       Date:  2015-07-08

3.  Global gene expression profiling of healthy human brain and its application in studying neurological disorders.

Authors:  Simarjeet K Negi; Chittibabu Guda
Journal:  Sci Rep       Date:  2017-04-18       Impact factor: 4.379

4.  A direct regulatory link between microRNA-137 and SHANK2: implications for neuropsychiatric disorders.

Authors:  Ana de Sena Cortabitarte; Simone Berkel; Flavia-Bianca Cristian; Christine Fischer; Gudrun A Rappold
Journal:  J Neurodev Disord       Date:  2018-04-17       Impact factor: 4.025

Review 5.  Glutamatergic Dysfunction and Synaptic Ultrastructural Alterations in Schizophrenia and Autism Spectrum Disorder: Evidence from Human and Rodent Studies.

Authors:  Ahmed Eltokhi; Andrea Santuy; Angel Merchan-Perez; Rolf Sprengel
Journal:  Int J Mol Sci       Date:  2020-12-23       Impact factor: 5.923

6.  Distinct contributions of GluA1-containing AMPA receptors of different hippocampal subfields to salience processing, memory and impulse control.

Authors:  Kasyoka Kilonzo; Daniel Strahnen; Vivien Prex; John Gems; Bastiaan van der Veen; Sampath K T Kapanaiah; Bhargavi K B Murthy; Stefanie Schulz; Rolf Sprengel; David Bannerman; Dennis Kätzel
Journal:  Transl Psychiatry       Date:  2022-03-14       Impact factor: 7.989

7.  Hippocampal subfield transcriptome analysis in schizophrenia psychosis.

Authors:  Jessica Marie Perez; Stefano Berto; Kelly Gleason; Subroto Ghose; Chunfeng Tan; Tae-Kyung Kim; Genevieve Konopka; Carol A Tamminga
Journal:  Mol Psychiatry       Date:  2020-03-09       Impact factor: 13.437

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.